Arcellx presents Phase I study of CART-ddBCMA: a CART-Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting